Effects of neoadjuvant and adjuvant therapy on sexual hormone levels, quality of life and sexual function in women with early breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024437

Enrollment

100

Registered

2021-03-22

Start date

2008-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50.9

Interventions

Group 1: Using validated questionnaires, quality of life and sexual function in women undergoing chemotherapy for early breast cancer are evaluated. Furthmore, the changes of the levels of sexual horm

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: - primary diagnosis of breast cancer - female patients - informed consent

Exclusion criteria

Exclusion criteria: - no active sexual life - previously treated depression - untreated thyroid dysfunction

Design outcomes

Primary

Measure	Time frame
Changes of sexual function and quality of life due to chemotherapy in women with breast cancer. Therefore, validated questionnaires before, during, at the end and six months after chemotherapy are being used.	—

Secondary

Measure	Time frame
Correlation of sexual function and hormonal changes during and after chemotherapy in women undergroing chemotherapy for breast cancer. Time points are before and during chemotherapy, at the ende and 6 months after completion of chemotherapy.	—

Countries

Germany

Contacts

Public ContactJuliane Farthmann

Universitätsfrauenklinik

juliane.farthmann@uniklinik-freiburg.de+4976127030020

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026